<!DOCTYPE html>
<html lang="en">
<head>
<meta name="robots" content="noindex, nofollow">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Hypotheses & Evidence — Judicialização da Saúde</title>
<style>
  :root {
    --bg: #f8f9fa; --card: #fff; --fg: #1a1a1a; --muted: #666;
    --border: #dee2e6; --accent: #0d6efd; --accent2: #198754;
  }
  * { box-sizing: border-box; margin: 0; padding: 0; }
  body {
    font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
    background: var(--bg); color: var(--fg); line-height: 1.5;
  }

  main {
    padding: 1.5rem 2rem 3rem; max-width: 900px; margin: 0 auto;
  }

  /* Markdown body styles */
  .md-body { font-size: .92rem; line-height: 1.7; color: #1f2328; }

  .md-body h1 { font-size: 1.5rem; font-weight: 600; margin: 1.8rem 0 .8rem; padding-bottom: .3rem; border-bottom: 1px solid var(--border); }
  .md-body h2 { font-size: 1.25rem; font-weight: 600; margin: 1.6rem 0 .6rem; padding-bottom: .25rem; border-bottom: 1px solid var(--border); }
  .md-body h3 { font-size: 1.05rem; font-weight: 600; margin: 1.3rem 0 .5rem; }
  .md-body h4 { font-size: .95rem; font-weight: 600; margin: 1.1rem 0 .4rem; }
  .md-body h5, .md-body h6 { font-size: .88rem; font-weight: 600; margin: 1rem 0 .4rem; }
  .md-body h1:first-child { margin-top: 0; }

  .md-body p { margin: 0 0 .8rem; }

  .md-body ul, .md-body ol { margin: 0 0 .8rem; padding-left: 1.8rem; }
  .md-body li { margin-bottom: .25rem; }
  .md-body li > ul, .md-body li > ol { margin-top: .25rem; margin-bottom: 0; }

  /* Task lists */
  .md-body ul li { list-style: disc; }
  .md-body li input[type="checkbox"] {
    margin-right: .4rem; vertical-align: middle; position: relative; top: -1px;
  }

  .md-body a { color: var(--accent); text-decoration: none; }
  .md-body a:hover { text-decoration: underline; }

  .md-body strong { font-weight: 600; }

  .md-body blockquote {
    margin: 0 0 .8rem; padding: .4rem 1rem;
    border-left: 4px solid var(--accent); background: #f0f4f8;
    color: #555; font-size: .88rem;
  }
  .md-body blockquote p:last-child { margin-bottom: 0; }

  .md-body code {
    font-family: "SFMono-Regular", Consolas, "Liberation Mono", Menlo, monospace;
    font-size: .85em; background: #eef1f5; padding: .15rem .35rem;
    border-radius: 4px;
  }
  .md-body pre {
    margin: 0 0 .8rem; padding: .9rem 1rem;
    background: #f6f8fa; border: 1px solid var(--border);
    border-radius: 6px; overflow-x: auto; line-height: 1.45;
  }
  .md-body pre code {
    background: none; padding: 0; font-size: .82rem;
  }

  .md-body table {
    width: 100%; border-collapse: collapse; margin: 0 0 .8rem;
    font-size: .85rem; display: block; overflow-x: auto;
  }
  .md-body th, .md-body td {
    padding: .45rem .7rem; border: 1px solid var(--border); text-align: left;
  }
  .md-body th { background: #f0f4f8; font-weight: 600; }
  .md-body tr:nth-child(even) td { background: #fafbfc; }

  .md-body hr {
    border: none; border-top: 1px solid var(--border); margin: 1.5rem 0;
  }

  .md-body img { max-width: 100%; }

  /* Collapsible sections */
  .doc-controls { margin-bottom: 1rem; }
  .doc-controls button {
    font-size: .8rem; padding: .3rem .7rem; cursor: pointer;
    background: var(--card); border: 1px solid var(--border); border-radius: 4px;
    color: var(--accent); font-weight: 600;
  }
  .doc-controls button:hover { background: #e7f1ff; }
  .md-body details { margin-bottom: .5rem; }
  .md-body details summary {
    font-weight: 600; cursor: pointer; list-style: none;
  }
  .md-body details summary::-webkit-details-marker { display: none; }
  .md-body details summary::before {
    content: "\25b6"; font-size: .7em; margin-right: .5rem;
    display: inline-block; transition: transform .15s;
  }
  .md-body details[open] summary::before { transform: rotate(90deg); }
  .md-body details.level-2 > summary {
    font-size: 1.25rem; padding-bottom: .25rem;
    border-bottom: 1px solid var(--border); margin: 1.6rem 0 .6rem;
  }
  .md-body details.level-3 > summary {
    font-size: 1.05rem; margin: 1.3rem 0 .5rem;
  }

  footer {
    text-align: center; padding: 1.5rem; font-size: .8rem; color: var(--muted);
    border-top: 1px solid var(--border); margin-top: 2rem;
  }
</style>
</head>
<body>

<style>
  .site-nav {
    position: sticky; top: 0; z-index: 100;
    background: #212529; display: flex; align-items: center;
    padding: 0 2rem; height: 3rem;
  }
  .site-nav .nav-brand {
    color: #fff; text-decoration: none; font-weight: 600; font-size: 1rem;
    margin-right: auto;
  }
  .site-nav .nav-brand:hover { color: #e9ecef; }
  .site-nav .nav-link {
    color: #adb5bd; text-decoration: none; font-size: .85rem;
    padding: 0 .75rem; height: 3rem; display: flex; align-items: center;
    background: none; border: none; cursor: pointer; font-family: inherit;
  }
  .site-nav .nav-link:hover, .site-nav .nav-link.active { color: #fff; }
  .nav-dropdown { position: relative; }
  .dropdown-menu {
    display: none; position: absolute; top: 3rem; right: 0;
    background: #fff; border: 1px solid var(--border); border-radius: 6px;
    box-shadow: 0 4px 16px rgba(0,0,0,.12); min-width: 220px;
    padding: .4rem 0; z-index: 200; max-height: 80vh; overflow-y: auto;
  }
  .nav-dropdown.open .dropdown-menu { display: block; }
  .dropdown-menu a {
    display: block; padding: .3rem 1rem; color: #1a1a1a;
    text-decoration: none; font-size: .82rem;
  }
  .dropdown-menu a:hover { background: #f0f4f8; }
  .dropdown-group-label {
    padding: .4rem 1rem .15rem; font-size: .68rem; font-weight: 700;
    color: #888; text-transform: uppercase; letter-spacing: .04em;
  }
  .dropdown-divider { border-top: 1px solid #eee; margin: .3rem 0; }
  .page-header {
    padding: .8rem 2rem; border-bottom: 1px solid var(--border); background: #fff;
  }
  .page-header h1 { font-size: 1.3rem; font-weight: 600; }
  .page-header p { color: var(--muted); font-size: .85rem; margin-top: .15rem; }
</style>

<nav class="site-nav">
  <a href="../index.html" class="nav-brand">Judicialização da Saúde</a>
  <a href="../paper/index.html" class="nav-link">Paper</a>
  <div class="nav-dropdown">
    <button class="nav-link active">Docs &#9662;</button>
    <div class="dropdown-menu">
    <div class="dropdown-group-label">Research reference</div>
    <a href="../docs/README.html">Project Overview</a>
    <a href="../docs/summary.html">Research Summary</a>
    <a href="../docs/institutions.html">Institutional Background</a>
    <a href="../docs/data.html">Data Sources</a>
    <a href="../docs/methods.html">Empirical Methods</a>
    <a href="../docs/literature.html">Literature</a>
    <a href="../docs/theory.html">Theoretical Framework</a>
    <a href="../docs/hypotheses.html">Hypotheses & Evidence</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Working notes</div>
    <a href="../docs/thinking.html">Open Questions & Ideas</a>
    <a href="../docs/decisions.html">Key Decisions</a>
    <a href="../docs/qa.html">Research Q&A</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Task tracking</div>
    <a href="../docs/todo.html">Active Tasks</a>
    <a href="../docs/done.html">Completed Tasks</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Communication</div>
    <a href="../docs/meetings.html">Meeting Notes</a>
    <a href="../docs/feedback.html">External Feedback</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Court analysis</div>
    <a href="../docs/01-stf-reasoning-templates.html">STF Reasoning Templates</a>
    <a href="../docs/02-stj-repetitivos-patterns.html">STJ Repetitivos Patterns</a>
    <a href="../docs/03-tjsp-plans-vs-sus.html">TJSP: Plans vs SUS</a>
    <a href="../docs/04-conitec-pcdt-vs-courts.html">CONITEC vs Courts</a>
    <a href="../docs/05-interfederative-responsibility.html">Interfederative Responsibility</a>
    </div>
  </div>
  <div class="nav-dropdown">
    <button class="nav-link">Data &#9662;</button>
    <div class="dropdown-menu">
    <a href="../sources/tjsp.html">TJSP</a>
    <a href="../sources/datajud.html">DataJud</a>
    <a href="../sources/stf-stj.html">STF & STJ</a>
    <a href="../sources/trf3.html">TRF3</a>
    <a href="../sources/spending.html">Municipal Spending</a>
    <a href="../sources/legislation.html">Health Legislation</a>
    </div>
  </div>
  <a href="../references/index.html" class="nav-link">References</a>
  <a href="../news/index.html" class="nav-link">News</a>
</nav>
<script>
document.querySelectorAll('.nav-dropdown > .nav-link').forEach(function(btn) {
  btn.addEventListener('click', function(e) {
    e.stopPropagation();
    var dd = btn.parentElement;
    var wasOpen = dd.classList.contains('open');
    document.querySelectorAll('.nav-dropdown.open').forEach(function(d) { d.classList.remove('open'); });
    if (!wasOpen) dd.classList.add('open');
  });
});
document.addEventListener('click', function() {
  document.querySelectorAll('.nav-dropdown.open').forEach(function(d) { d.classList.remove('open'); });
});
</script>

<div class="page-header">
  <h1>Hypotheses & Evidence</h1>
</div>

<main>
<div class="doc-controls">
  <button id="toggle-sections">Expand all</button>
</div>
<div class="md-body">
<h1>Hypotheses — Theory-Evidence Scorecard</h1>
<p>Role: Structured mapping of theoretical frameworks to pre-existing evidence and testable predictions. Each hypothesis links a theory from <code>theory.md</code> to existing quantitative/qualitative evidence and specifies the empirical test the Judge-IV design can run. Cross-references <code>data.md</code> for data sources.</p>
<p>Status: Updated Feb 2026 after NotebookLM investigation of reference documents (see <code>docs/notebooklm_hypothesis_responses.md</code>). Evidence assessments based on project documentation, curated news stories, reference reports (CNJ/Insper 2019, IPEA 2025, Fiocruz 2020, TCU), and structured queries against the full reference corpus.</p>
<hr />
<h2 id="how-to-read-this-document">How to read this document</h2>
<p>Each hypothesis entry contains:</p>
<ul>
<li><strong>Theory:</strong> Which framework from <code>theory.md</code> generates the prediction</li>
<li><strong>Prediction:</strong> What the theory says should happen</li>
<li><strong>Pre-existing evidence:</strong> What we already know (with sources)</li>
<li><strong>Evidence strength:</strong> How well the existing evidence supports/contradicts the prediction</li>
<li><strong>Empirical test:</strong> How the Judge-IV design can adjudicate the hypothesis</li>
<li><strong>Data requirements:</strong> Which datasets are needed</li>
<li><strong>Priority:</strong> Based on (evidence strength) x (testability with our design)</li>
</ul>
<p>Evidence strength ratings:</p>
<ul>
<li><strong>Very strong:</strong> Multiple independent quantitative sources, consistent direction</li>
<li><strong>Strong:</strong> Quantitative evidence from at least one credible source, supported by qualitative evidence</li>
<li><strong>Moderate:</strong> Primarily qualitative or anecdotal, or quantitative but contested</li>
<li><strong>Weak:</strong> Theoretically motivated but little direct evidence</li>
</ul>
<hr />
<h2 id="overall-assessment">Overall assessment</h2>
<p>The pre-existing evidence tilts heavily toward the <strong>pessimistic view</strong> (courts as distortionary). The evidence on supplier-induced demand, procurement waste, vertical fiscal mismatch, and regressive selection is substantial and comes from multiple independent sources. However, real counter-evidence on administrative failure (80% of cities with medicine shortages, CONITEC incorporation delays averaging 648 days, federal stockpiles destroyed) keeps the <strong>corrective view</strong> alive.</p>
<p>A critical insight from the NotebookLM investigation: <strong>the corrective-vs-distortionary balance is context-dependent, not uniform.</strong> The on-list/off-list composition of judicial demands varies dramatically — from majority on-list in Pará (courts correcting admin failure) to 76% off-list in Campinas (courts imposing new obligations). The overall IV estimate will be a weighted average of these two margins, and the heterogeneity analysis is where theories differentiate most sharply.</p>
<p>Additionally, during our main sample period (pre-2024), judges operated with <strong>essentially zero technical screening</strong>: NAT-Jus was cited in only 0.01% of SP first-instance decisions (9 of 107,497 cases). The 93% grant rate combined with near-zero technical consultation means the Judge-IV captures a regime of pure judicial discretion. The 2024 reforms (mandatory NAT-Jus consultation, nullity of prescription-only decisions) represent a regime change.</p>
<p>The paper's contribution is resolving this with causal estimates. The heterogeneity analysis is where theories differentiate most sharply — different mechanisms predict different patterns of who benefits and who loses from judicial mandates.</p>
<hr />
<h2 id="tier-1-very-strong-pre-existing-evidence">Tier 1: Very Strong Pre-Existing Evidence</h2>
<h3 id="h1-judicial-spending-crowds-out-primary-care">H1. Judicial spending crowds out primary care</h3>
<p><strong>Theory:</strong> Optimal Earmarking (#4) + Health Capital (#3)</p>
<p><strong>Prediction:</strong> Judicial mandates function as rigid earmarks that shift municipal spending from discretionary primary care (subfunção 301) toward pharmaceutical assistance (subfunção 303). Crowd-out of primary care increases avoidable hospitalizations (ICSAP).</p>
<p><strong>Pre-existing evidence:</strong></p>
<ul>
<li>Minas Gerais: judicialization consumes ~11% of state health budget. &quot;When someone sues for a specific treatment, resources meant for the collective end up going to a single case.&quot; [SES-MG institutional page]</li>
<li>Campinas: R$47.7M on court-ordered pharma (2017–2021); 76% involved items absent from SUS lists, 23.7% were state/federal responsibility. [Jornal da Unicamp 2024]</li>
<li>SP municipality: judicial spending = 6% of pharma budget, 10% of medication/supplies budget. [Wang SciELO/RAP 2020]</li>
<li>Conjur analysis: &quot;individualized technology-driven model undermines constitutional priority of prevention, primary care, and health surveillance.&quot; [Conjur 2024]</li>
<li>Fund seizures described as &quot;catastrophic&quot; for fiscal planning. [CNJ/Insper 2019, p. 202]</li>
<li>Only 50–60% of municipal health secretariats have dedicated legal units. [CNJ 2021, p. 270]</li>
<li>~270 municipalities spent 30–100% of entire health budgets on judicialized demands in 2020. [The Conversation/Metrópoles 2024]</li>
<li>Juiz de Fora: judicialization described as &quot;break in the regular flow of bed regulation&quot;; primary care shows long waits, doctor shortages. [Tribuna de Minas 2026]</li>
<li>Fiocruz describes current model as &quot;catastrophic&quot; for local fiscal planning, undermining constitutional priority for prevention and primary care. [Fiocruz Judicializacao Municipios 2020, p. 571; Ipea Direito Saude Macrojustica 2020, p. 513]</li>
</ul>
<p><strong>Evidence strength: Strong.</strong> Qualitative evidence is abundant and consistent. Quantitative crowd-out at the subfunção level has not been causally estimated — that is our core contribution.</p>
<p><strong>Empirical test:</strong> Judge-IV effect on spending composition across TCE-SP subfunções (301 vs. 302 vs. 303). Second stage: effect on ICSAP hospitalizations (avoidable admissions signaling primary care failure).</p>
<p><strong>Data:</strong> TCE-SP Despesas (subfunção-level) + DATASUS SIH (ICSAP)</p>
<p><strong>Priority: Highest.</strong> This is the paper's central result.</p>
<hr />
<h3 id="h2-supply-driven-litigation-has-lower-health-returns">H2. Supply-driven litigation has lower health returns</h3>
<p><strong>Theory:</strong> Supplier-Induced Demand (#10)</p>
<p><strong>Prediction:</strong> Litigation driven by the lawyer-doctor-pharma supply chain (rather than genuine patient need) concentrates on high-margin, non-formulary drugs and produces lower health returns per mandate than demand-driven cases.</p>
<p><strong>Pre-existing evidence:</strong></p>
<ul>
<li>19 lawyers filed ~63% of all SP health lawsuits (2006); for some drugs, one lawyer filed 70% of actions. [Chieffi &amp; Barata 2009, SciELO/RSP]</li>
<li>6 lawyers responsible for 35% of all state cases; single physician wrote 66% of prescriptions for a specific judicialized drug. [TCU Orçamento Judicialização]</li>
<li>Eculizumab: single law firm filed ~70% of 514 federal actions; 73% originated in DF; roughly half lacked confirmed diagnosis. [Folha 2020]</li>
<li>Operação Garra Rufa (2008): criminal network of 3 pharma labs, NGO, doctors, lawyers defrauded R$63M. Many patients didn't know suits were filed on their behalf. [Gov SP 2008]</li>
<li>Operação Cálice de Hígia (2017): after enforcement, eculizumab purchases fell 49.5%, price dropped 35%. [Folha 2020] — near-smoking-gun evidence that supply disruption reduced volume without observable health harm.</li>
<li>MG study (1999–2009): single doctor from one law office responsible for ~44% of prescriptions in 117 actions. Greater concentration for newer, more expensive medications. [SciELO/RSP 2014]</li>
<li>Pharma targets medical students/residents via philanthropy-disguised marketing. [SciELO/RSP 2014]</li>
<li>&quot;Dangerous liaisons&quot; between pharma, patient associations, and judicial battles documented as market expansion strategy. [SciELO/Physis 2012]</li>
</ul>
<p><strong>Evidence strength: Very strong.</strong> Multiple independent quantitative sources documenting extreme concentration. The enforcement natural experiments (Garra Rufa, Cálice de Hígia) provide quasi-causal evidence that supply-side disruption reduces litigation without health costs.</p>
<p><strong>Empirical test:</strong> Split sample by lawyer volume (high-volume private attorneys vs. Defensoria/low-volume). Compare Judge-IV health returns across subsamples. If SID dominates, the supply-driven margin should show lower (possibly zero or negative) health returns. Also test: do lenient judges differentially attract supply-side cases?</p>
<p><strong>Data:</strong> TJSP case data (lawyer identity) + DATASUS outcomes</p>
<p><strong>Priority: Very high.</strong> The paper's supply-side section (Sec 7.4) already documents these patterns. The causal test via heterogeneous IV estimates would be a major contribution.</p>
<hr />
<h3 id="h3-judicial-spending-is-less-efficient-than-administrative-spending">H3. Judicial spending is less efficient than administrative spending</h3>
<p><strong>Theory:</strong> Procurement Moral Hazard (#7) + Health Capital (#3)</p>
<p><strong>Prediction:</strong> Court-ordered procurement bypasses competitive bidding, pays premium prices, and channels spending to high-cost specialized drugs (flat of the production function). Returns to judicially induced spending should be systematically lower than returns to administratively allocated spending.</p>
<p><strong>Pre-existing evidence:</strong></p>
<ul>
<li>30–44% price premium for judicial vs. standard SUS procurement. [Genicolo-Martins &amp; Furquim de Azevedo 2024]</li>
<li>R$26.4M in judicially purchased medicines expired 2018–2022. [TCU audit 2024]</li>
<li>R$2.7B annual judicial bill = entire SAMU budget, one-third of Mais Médicos, nearly half of Brasil Sorridente — serving only ~6,000 patients. [Câmara dos Deputados 2025]</li>
<li>70% of five-year federal judicial spending went to just 10 medications. [Fala Você Notícias 2025]</li>
<li>BioMarin delayed CONITEC submission for vosoritida while courts forced purchases at full price: R$875M judicial spend (2022–2024). [Futuro da Saúde 2025]</li>
<li>Auramedi: 1-employee company won R$285.8M no-bid contract. [Metrópoles 2023]</li>
<li>Zolgensma: after risk-sharing incorporation, Brazil achieved lowest global price. Pre-incorporation, families sued for full-price purchases. [Gov.br/Secom 2025]</li>
<li>SP state spent R$40M (2006–2007) on seven anticancer drugs via court orders; R$7M lacked clinical evidence of benefit. [FAPESP Pesquisa 2025]</li>
<li>Fund seizures (bloqueios) lead to purchases at private pharmacies at full market prices, bypassing even the PMVG ceiling. [Evidências Jornalísticas, p. 537]</li>
<li>Post-2024 Tema 1.234 mandates PMVG price cap, but &quot;often ignored&quot; when individuals make purchases directly following court orders. [Stf Temas Desafios Academico, p. 1118]</li>
<li>Three-way classification of off-list drugs: (a) never evaluated by CONITEC — &quot;very high&quot; litigation level; (b) rejected by CONITEC — &quot;high&quot; litigation; (c) strategically withheld from CONITEC by pharma. [Sintese Conitec PCDT vs Tribunais, p. 988; Evidências Jornalísticas, p. 538]</li>
</ul>
<p><strong>Evidence strength: Very strong.</strong> Price premium well-documented from multiple sources. The Zolgensma incorporation before/after provides a natural calibration. The three-way off-list classification reveals that the highest litigation concentrates on drugs CONITEC has never evaluated — consistent with strategic non-submission by pharma.</p>
<p><strong>Empirical test:</strong> Compare returns to judicial spending (Judge-IV) vs. administrative spending (federal transfer IV) on the same health outcomes. If procurement waste is real, returns to judicial spending should be systematically lower per R$ spent.</p>
<p><strong>Data:</strong> TCE-SP + SIOPS (spending) + DATASUS (outcomes)</p>
<p><strong>Priority: Very high.</strong> The dual-IV comparison is a distinctive feature of the paper's design.</p>
<hr />
<h3 id="h4-vertical-fiscal-mismatch-amplifies-negative-effects">H4. Vertical fiscal mismatch amplifies negative effects</h3>
<p><strong>Theory:</strong> Fiscal Federalism and Unfunded Mandates (#9)</p>
<p><strong>Prediction:</strong> Municipalities ordered to pay for drugs that are administratively the state's or Union's responsibility face the largest fiscal shocks and worst downstream health effects. Effects should be larger in municipalities with less fiscal capacity.</p>
<p><strong>Pre-existing evidence:</strong></p>
<ul>
<li>55% of SP municipal judicial pharma spending was for state/federal-responsibility drugs. [Wang 2014; SciELO/RAP 2020]</li>
<li>Pre-2024, no systematic reimbursement existed — municipalities bore full cost. [Institutional fact; confirmed by reimbursement Portaria only in 2023]</li>
<li>Small municipalities (&lt;5,000 pop): highest per capita judicial medication cost at R$81.75. [IPEA 2025]</li>
<li>Sidrolândia (MS): receives R$46,900/month in transfers, spends R$219,700/month of own funds. [Região News 2025]</li>
<li>Reimbursement suspended 2017–2023 (six years). [Agência Gov 2023]</li>
<li>Tema 793 (2019) required redirecting compliance to responsible entity, but implementation lagged. [STF Tema 793]</li>
<li>Tema 1.234 (2024): Union reimburses 65% (80% oncology) for non-incorporated drugs. [STF Tema 1.234]</li>
<li>100% of municipalities &gt;500k have active litigation; 36.5% of municipalities &lt;5k report court-ordered medication provision. [IPEA 2025]</li>
<li>Nationwide, approximately 76% of judicial demands in some samples involved items absent from SUS lists. [Ipea Gastos Judicializacao 2025, p. 458]</li>
<li>Municipalities frequently ordered to pay for &quot;ultra-high-cost&quot; drugs and high-complexity procedures they do not operate or have technical capacity to manage. [Fiocruz Judicializacao Municipios 2020, p. 570]</li>
<li>Federal share of SUS financing fell from 45.3% (2012) to 37.6% (2022), shifting burden to municipalities more exposed to judicial shocks. [Piaui O Complexo Parte II, p. 915]</li>
</ul>
<p><strong>Evidence strength: Very strong.</strong> The 55% mismatch statistic is a powerful calibration number. The 76% off-list figure confirms that most mandates impose genuinely new obligations rather than correcting delivery of existing formulary items. The institutional timeline (no reimbursement → partial reimbursement) provides clean natural variation. <strong>Gap:</strong> No systematic estimate of CBAF vs. CEAF/CESAF composition across the full universe of cases — just case studies (SP 55%, Campinas 23.7%). Our data could potentially fill this.</p>
<p><strong>Empirical test:</strong> Heterogeneity by fiscal capacity (own-source revenue share) and by whether mandated items are within municipal responsibility (CBAF/Group 3) vs. misassigned (CEAF/CESAF). Pre/post Tema 793 (2019) and 2024 reimbursement reform as natural breaks.</p>
<p><strong>Data:</strong> TCE-SP Despesas + Receitas (fiscal capacity) + TJSP case data (drug type where available)</p>
<p><strong>Priority: Very high.</strong> Well-documented mechanism with clear empirical test and data.</p>
<hr />
<h2 id="tier-2-strong-evidence-directly-testable">Tier 2: Strong Evidence, Directly Testable</h2>
<h3 id="h5-litigation-is-regressive-defensoria-presence-moderates">H5. Litigation is regressive; Defensoria presence moderates</h3>
<p><strong>Theory:</strong> Litigation Selection and Distribution (#8) — Shavell, Bebchuk, Galanter</p>
<p><strong>Prediction:</strong> Health litigation skews toward better-resourced plaintiffs. Where Defensoria Pública is present, litigation composition shifts toward lower-income plaintiffs and potentially more progressive health effects.</p>
<p><strong>Pre-existing evidence:</strong></p>
<ul>
<li>Only ~20% of health litigants identified as economically vulnerable. [CNJ 2021, p. 269]</li>
<li>Private attorneys: 64% of SP cases; Defensoria: only 13.8%; prosecutors 9%. [Chieffi SP data 2010–2014]</li>
<li>Defensoria share of TJSP first-instance volume: ~6.91%. [TJSP Sentencas Summary]</li>
<li>Defensoria presence = 7x increase in probability of municipality having medicine lawsuit. [Biehl et al. 2015, Cad. Saúde Pública]</li>
<li>72% of comarcas lacked public defenders (2013); still 41% by 2024. [IPEA/ANADEP 2013; Conjur 2025]</li>
<li>&quot;Judicialization accentuates inequality in access.&quot; [Chieffi SES-SP]</li>
<li>Counter-evidence: scoping review calls evidence on regressivity &quot;inconclusive.&quot; [Int. J. Equity in Health 2019]</li>
<li>Counter-evidence: some studies find majority of litigants are poor/older individuals. [Int. J. Equity in Health 2019]</li>
<li>RJ CRLS extrajudicial chamber: 57.5% of cases resolved without litigation, savings of R$3.5M+. [Defensoria RJ 2025]</li>
</ul>
<p><strong>Evidence strength: Strong but contested.</strong> The private-attorney dominance and Defensoria access gap are well-documented. But genuine counter-evidence exists. The ambiguity makes this a high-value hypothesis to resolve causally.</p>
<p><strong>Empirical test:</strong> Heterogeneity by municipality income/HDI and Defensoria presence (from IPEA/ANADEP data). If regressive: judicial spending widens health outcome gaps. If Defensoria moderates: effects more progressive where Defensoria coverage is stronger. Can also split TJSP sample by representation type (Defensoria vs. private attorney).</p>
<p><strong>Data:</strong> TJSP case data (representation type) + census/HDI data + IPEA Defensoria coverage maps + DATASUS outcomes</p>
<p><strong>Priority: High.</strong> Resolves an important empirical question that the descriptive literature has not settled.</p>
<hr />
<h3 id="h6-behavioral-biases-drive-over-granting-information-reforms-improve-allocation">H6. Behavioral biases drive over-granting; information reforms improve allocation</h3>
<p><strong>Theory:</strong> Behavioral Judicial Decision-Making (#12) — identifiable victim effect, omission bias, anchoring</p>
<p><strong>Prediction:</strong> Judges systematically over-grant due to identifiable victim effect and omission bias. Information interventions (NAT-Jus) reduce anchoring on plaintiff evidence, increase case discrimination, and improve allocative efficiency of mandates.</p>
<p><strong>Pre-existing evidence:</strong></p>
<ul>
<li>Grant rate ~93% for medication/treatment cases against municipalities, despite heterogeneous clinical merit. [TJSP sentença data]</li>
<li>&lt;6% of decisions cite CONITEC or RENAME technical standards. [CNJ/Insper 2019, p. 91]</li>
<li><strong>NAT-Jus citation in SP first-instance: 0.01%</strong> — only 9 of 107,497 decisions formally cited NAT-Jus. [Cnj Insper Relatorio Analitico 2019, p. 135, 179]</li>
<li>Second-instance (national, 2008–2017): only 0.31% of 164,000+ acórdãos cited NAT-Jus. [Cnj Insper Relatorio Analitico 2019, p. 136, 234]</li>
<li>NAT-Jus Roraima (2019–2024): only 12.3% of cases classified as &quot;urgent&quot; were genuinely urgent; 66.5% non-urgent. Goiás: 18.1% truly urgent vs. 81.9% not. [Migalhas 2024]</li>
<li>Judges describe &quot;deciding under pressure about a subject we do not master because we are not doctors.&quot; [Portal CNJ 2020]</li>
<li><strong>&quot;Ditadura do médico&quot;</strong>: judges defer automatically to plaintiff's private prescription because they lack technical mastery to contradict a medical professional. [Cnj Insper Relatorio Analitico 2019, p. 200]</li>
<li><strong>Selective citation pattern</strong>: judges are more likely to cite ANVISA/CONITEC when <em>inclined to deny</em>, using technical standards to ground an unfavorable ruling — not as genuine screening. [Cnj Insper Relatorio Analitico 2019, p. 180]</li>
<li>Judge resistance to NAT-Jus: perceived threat to judicial autonomy, lack of institutional routine, missing digital infrastructure in certain comarcas. [Cnj Insper Relatorio Analitico 2019, p. 201]</li>
<li>53.8% of NAT-Jus opinions are fully favorable to patient — so NAT-Jus does not rubber-stamp denials. [Migalhas 2024]</li>
<li><strong>Enormous geographic variation</strong> in NAT-Jus usage: Mato Grosso 18.05% citation rate; Mato Grosso do Sul 3.56%; Rio de Janeiro 2.7% (pioneer, est. 2012); São Paulo 0.01%. [Cnj Insper Relatorio Analitico 2019, p. 234, 236]</li>
<li>Post-Tema 1.234 (2024): technical notes grew 32% (~131k vs. ~99k in 2024). Notes for non-incorporated drugs rose 40%. [Evidências Jornalísticas, p. 449–450]</li>
<li>Post-Tema 1.234: SUS lawsuits declined ~6–7% in H1 2025. [Correio Braziliense 2025]</li>
<li><strong>2024 regime change</strong>: NAT-Jus consultation now mandatory for non-incorporated ANVISA-registered drugs; decisions based solely on prescriptions subject to nullification. [Stf Temas 6 1234 Manual Pge, p. 1108–1109; Sumulas Vinculantes 60 61 Saude, p. 1140]</li>
<li>Tema 106 (2018) had minimal impact: grant rates remained ~93%, only 4% filing dip. [CNJ/Insper 2019]</li>
<li>CNJ diagnostic: injunction approval rates above 85% in six states; conciliation rates below 1% in 17 states. [Portal CNJ 2025]</li>
</ul>
<p><strong>Evidence strength: Very strong</strong> (upgraded from Strong). The 0.01% citation rate in SP first-instance is a decisive number: during our sample period, judges decided 107,000+ cases with essentially zero technical input. Combined with the 93% grant rate, selective citation only when denying, and the &quot;ditadura do médico&quot; framing, this constitutes compelling evidence of systematically uninformed decision-making. The geographic variation (MT 18% vs. SP 0.01%) directly motivates a cross-state heterogeneity test. The 2024 mandatory consultation + nullity reform creates a sharp pre/post break.</p>
<p><strong>Empirical test:</strong> Within-judge variation: do judges who consult NAT-Jus show more heterogeneous grant rates (discriminating between cases) and better downstream health outcomes per mandate? Geographic variation in NAT-Jus adoption as cross-sectional test (though limited within SP due to near-zero adoption). Pre/post Tema 1.234 (2024) as regime-change test. The pre-2024 period (our main sample) captures pure judicial discretion with no technical screening — this is important context for interpreting the IV estimates.</p>
<p><strong>Data:</strong> TJSP case data (grant rates by judge, over time) + DATASUS outcomes</p>
<p><strong>Priority: High.</strong> Tests whether the institutional reform path (better information for judges) actually works. Policy-relevant. The 0.01% figure is also powerful framing for the paper's motivation.</p>
<hr />
<h3 id="h7-mandate-accumulation-worsens-effects-over-time-ratchet">H7. Mandate accumulation worsens effects over time (ratchet)</h3>
<p><strong>Theory:</strong> Dynamic Commitment and Ratchet Effects (#11)</p>
<p><strong>Prediction:</strong> Each mandate creates a recurring budget obligation. The stock of active mandates (not just the flow of new cases) drives fiscal pressure and health outcomes. Effects worsen as mandates accumulate, progressively rigidifying municipal budgets.</p>
<p><strong>Pre-existing evidence:</strong></p>
<p><em>Aggregate trends (flow):</em></p>
<ul>
<li>Federal judicial medication spending: R$70M (2008) → R$1B (2015) → R$2.7B (2024). [TCU 2017; IPEA 2025]</li>
<li>Volume doubling post-2020: 76,836 (2020) → 162,046 (2024) first-instance cases. [IPEA 2025]</li>
<li>Monthly health lawsuits rose from 21,000 (2020) to 61,000 (2024). [Agência Brasil 2024]</li>
<li>MS: 6,500 (2023) → 7,659 (2024) lawsuits, with 810 new actions by Feb 2025 alone. State prosecutor: &quot;seizure of public resources.&quot; [Campo Grande News 2025]</li>
<li>Tema 106 (2018): minimal impact — 4% dip in filings, grant rates unchanged. Evidence of precedent ratchet (hard to reverse established judicial patterns). [CNJ/Insper 2019]</li>
</ul>
<p><em>Stock of active mandates (new from NotebookLM investigation):</em></p>
<ul>
<li><strong>National stock:</strong> Cumulative active health cases surpassed 2.5 million; as of August 2025, approximately 880,000 processes pending. [Evidências Jornalísticas, p. 447]</li>
<li><strong>São Paulo (2015):</strong> Stock of <strong>42,868 active processes</strong>. [Cnj Insper Justica Pesquisa, p. 205]</li>
<li><strong>Rio Grande do Sul (2017):</strong> Stock of <strong>90,000 active lawsuits</strong> serving approximately <strong>61,000 &quot;judicial patients&quot;</strong> simultaneously. [Cnj Insper Justica Pesquisa, p. 209]</li>
<li><strong>Campinas:</strong> Managed <strong>539 active processes</strong> simultaneously (2017–2021), covering <strong>378 different medication types</strong>. [Evidências Jornalísticas, p. 458]</li>
<li>Average time to final judgment: <strong>432 days</strong>, meaning mandates remain active as preliminary orders for years. [Stf Temas Desafios Academico, p. 1112]</li>
</ul>
<p><em>Micro-level ratchet/waste evidence (new):</em></p>
<ul>
<li><strong>Araguaína (TO) audit:</strong> A judge held 20 follow-up hearings for active medication mandates and found that <strong>only 3 of 20 patients (15%) still actually needed the medicine</strong>; the remaining 17 continued to receive it despite no longer requiring it. [Cnj Insper Justica Pesquisa, p. 301]</li>
<li><strong>Enunciado 2</strong> requires periodic renewal of medical reports for continuous treatments, with clear therapeutic goals — acknowledging the ratchet problem. [Enunciados Jornadas Saude Consolidado, p. 399]</li>
<li><strong>Enunciado 70:</strong> If a patient fails to collect medication for 3 consecutive months, it constitutes &quot;abandonment of treatment,&quot; allowing suspension. [Enunciados Jornadas Saude Consolidado, p. 413]</li>
<li>Some judges have begun inserting <strong>8-month time limits</strong> in sentences, requiring new prescription and clinical review for renewal. [Cnj Insper Justica Pesquisa, p. 300]</li>
</ul>
<p><strong>Evidence strength: Very strong</strong> (upgraded from Strong). The Araguaína audit is direct micro-level evidence of the ratchet: 85% of patients in one sample no longer needed the medication they were receiving under active court orders. Combined with the RS stock figure (90,000 active lawsuits / 61,000 judicial patients simultaneously) and the Campinas complexity data (539 processes / 378 medication types), the evidence now supports both the aggregate acceleration and the micro-level waste mechanism. The judiciary's own corrective enunciados (2 and 70) confirm the problem is recognized but weakly addressed.</p>
<p><strong>Empirical test:</strong> Event-study specification explicitly framed as testing ratchet effects — not just timing but accumulation. Stock vs. flow distinction in the first stage: current-year judge assignments (flow) vs. accumulated mandates over judge's tenure (stock). Test whether effects are convex in cumulative exposure (nonlinear costs of rigidity). The Araguaína finding implies that the marginal return to the <em>stock</em> of judicial spending is near zero for a large share of continuing mandates, which drags down the average return estimated by the Judge-IV.</p>
<p><strong>Data:</strong> TJSP panel data (judge-municipality-year) + TCE-SP + DATASUS</p>
<p><strong>Priority: Very high</strong> (upgraded from High). The stock data and Araguaína audit provide much stronger micro-level foundations than previously available. The ratchet is underexplored in the literature and maps cleanly to the event-study design.</p>
<hr />
<h2 id="tier-3-plausible-partially-testable">Tier 3: Plausible, Partially Testable</h2>
<h3 id="h8-courts-are-corrective-where-administrative-capacity-is-weakest">H8. Courts are corrective where administrative capacity is weakest</h3>
<p><strong>Theory:</strong> Regulatory Capture and Second-Best Courts (#5)</p>
<p><strong>Prediction:</strong> If courts serve as second-best corrections to captured or dysfunctional administration, judicial mandates should have more positive health effects in municipalities with weaker administrative capacity (more corruption, less health infrastructure, worse SUS delivery).</p>
<p><strong>Pre-existing evidence for administrative failure (supporting the corrective view):</strong></p>
<ul>
<li>80% of Brazilian cities reported medicine shortages, including basic items: amoxicillin (68%), dipirona (66%) (CNM survey of 3,360 municipalities, 2022). [Agência Brasil/Radioagência 2022; Evidências Jornalísticas, p. 491]</li>
<li>Shortages are <strong>structural, not temporary</strong>: Brazil's domestic production of active pharmaceutical ingredients fell from 50% to 5% of needs over 40 years. [Fiocruz/EPSJV 2022; Evidências Jornalísticas, p. 491]</li>
<li>76 of 242 CONITEC-incorporated items (31.4%) unavailable after average <strong>648 days</strong> — three times the legal deadline. Long-acting insulin analogs unavailable for over <strong>2,000 days</strong> after incorporation. [Folha 2025; Evidências Jornalísticas, p. 492–493]</li>
<li>Zero of 25 audited medications met the 180-day legal incorporation deadline; average delay 624 days. [A Regra é Clara 2022]</li>
<li>R$13.5M in rare disease drugs incinerated under Bolsonaro administration while municipalities forced to buy via emergency procurement. [Folha 2023]</li>
<li>1.6 million Brazilians on SUS surgical waiting lists; 5% die per year waiting. [SciELO/CSP]</li>
<li><strong>On-formulary lawsuits framed as &quot;management problems&quot;</strong>: drugs already in RENAME/CEAF unavailable due to stockouts. Very high plaintiff success rate. [Cnj Insper Relatorio Analitico 2019, p. 194, 211, 236]</li>
<li><strong>On-list share varies dramatically</strong>: Pará — &quot;majority&quot; of judicialization involved RENAME drugs; SP state — ~25% on-list; Campinas — 24% on-list; federal level — majority off-list. [Cnj Insper Relatorio Analitico 2019, p. 194; Evidências Jornalísticas, p. 448, 458]</li>
<li>Information and bureaucratic barriers: patients find administrative paths to obtain medication &quot;unintelligible or complex.&quot; [Cnj Insper Relatorio Analitico 2019, p. 188]</li>
</ul>
<p><em>Variation across municipalities (new from NotebookLM):</em></p>
<ul>
<li><strong>Successful municipalities:</strong> Araraquara (SP) reduced health lawsuits by 70% through pre-litigation committees. [Evidências Jornalísticas, p. 530]</li>
<li><strong>Chronic failure:</strong> In Santa Quitéria do Maranhão, a baby died because the local hospital lacked a pediatrician, incubator, or neonatal ICU despite the city receiving millions in federal health transfers. [Piaui Farra Ilimitada, p. 898–900]</li>
<li><strong>Fraudulent variation:</strong> Municipalities in Maranhão inflated procedure numbers (claiming more HIV tests than the city of São Paulo) to increase federal budget ceilings while actual delivery remained poor. [Piaui Farra Ilimitada, p. 845–847]</li>
</ul>
<p><strong>Pre-existing evidence for litigation capture (undermining the corrective view):</strong></p>
<ul>
<li>All evidence under H2 (lawyer concentration, fraud operations, pharma networks)</li>
<li>CONITEC also shows capture: industry provided 70.7% of public consultation contributions; Spinraza approved after AG intervention with no new evidence. [Tamachiro et al. 2022; Caetano et al. 2019]</li>
<li>52.7% of industry-led CONITEC requests rejected; pharma companies strategically avoid submission when evidence is weak, preferring judicial channel with &gt;80% success rate. [Evidências Jornalísticas, p. 538]</li>
<li>Litigation levels are &quot;Very High&quot; for drugs never evaluated by CONITEC — consistent with strategic non-submission. [Sintese Conitec PCDT vs Tribunais, p. 988]</li>
</ul>
<p><strong>Evidence strength: Strong</strong> (upgraded from Moderate). The NotebookLM investigation sharpened the evidence substantially. The on-list/off-list variation across contexts (Pará majority on-list vs. Campinas 76% off-list) shows the corrective mechanism operates unevenly — courts correct admin failure for on-list drugs in some jurisdictions but impose new obligations for off-list drugs in others. The municipal variation evidence (Araraquara success vs. Maranhão failure) directly supports using administrative capacity as a heterogeneity dimension. The strategic non-submission evidence strengthens the capture side.</p>
<p><strong>Empirical test:</strong> Heterogeneity by municipal administrative capacity (health infrastructure indices, ESF coverage, corruption measures). The <strong>on-list vs. off-list split</strong> is the cleanest discriminating test: on-list mandates (correcting admin failure) should have positive or neutral returns; off-list mandates (especially never-evaluated drugs) should have low or negative returns net of crowd-out. If corrective: more positive effects where capacity is weakest and where on-list share is highest. If captured: negative effects concentrated where supply-side litigation is strongest and off-list share is highest.</p>
<p><strong>Data:</strong> Municipal capacity indices + TJSP case data (drug classification crosswalked against RENAME/CEAF) + DATASUS</p>
<p><strong>Priority: High</strong> (upgraded from Medium-high). The on-list/off-list split is now the primary discriminating test between the corrective and distortionary views, supported by rich pre-existing evidence on both sides.</p>
<hr />
<h3 id="h9-property-rule-enforcement-is-inefficient-for-standard-treatments">H9. Property-rule enforcement is inefficient for standard treatments</h3>
<p><strong>Theory:</strong> Property Rules vs. Liability Rules (#6) — Calabresi &amp; Melamed</p>
<p><strong>Prediction:</strong> Injunctive orders (&quot;must provide&quot;) are efficient only for hard-to-value health conditions (rare diseases, emergencies). For easily valued standard treatments (drugs with known prices, SUS alternatives available), liability-style administrative processes with appeal mechanisms dominate.</p>
<p><strong>Pre-existing evidence:</strong></p>
<ul>
<li>Courts predominantly use property-rule enforcement: 85% preliminary injunction grant rate; direct fund seizure from bank accounts. [Wang &amp; Ferraz 2013; STJ Tema 84]</li>
<li>1 in 4 judicially ordered drugs already on SUS list — these are clearly cases where administrative process should suffice. [Folha 2018]</li>
<li>52.1% of municipalities have created extrajudicial provision mechanisms. [IPEA 2025]</li>
<li>RJ CRLS resolved 57.5% of cases without litigation. [Defensoria RJ 2025]</li>
<li>Amazonas extrajudicial chamber: 89.7% resolution rate. [TJAM 2024]</li>
<li>Joinville NAT-Jus: new actions fell 36.6% after establishment. [NSC Total 2019]</li>
</ul>
<p><strong>Evidence strength: Moderate.</strong> The success of extrajudicial resolution mechanisms (57–90% resolution rates) indirectly supports the prediction that many cases don't require injunctive enforcement. But direct comparison of property-rule vs. liability-rule outcomes is not available.</p>
<p><strong>Empirical test:</strong> Heterogeneity by claim type (on-formulary vs. off-formulary; standard vs. non-standard treatments). Property-rule enforcement should be more wasteful for on-formulary drugs (where admin process works) and potentially justified for off-formulary rare disease treatments.</p>
<p><strong>Data:</strong> TJSP case data (claim classification) + DATASUS</p>
<p><strong>Priority: Medium.</strong> Predictions overlap substantially with H1 and H3.</p>
<hr />
<h3 id="h10-pharma-strategically-delays-incorporation-to-profit-from-judicial-channel">H10. Pharma strategically delays incorporation to profit from judicial channel</h3>
<p><strong>Theory:</strong> Procurement Moral Hazard (#7) — specifically the entry/delay incentive</p>
<p><strong>Prediction:</strong> Pharmaceutical companies avoid CONITEC submission when judicial channel yields higher profits. Litigation concentrates on drugs where the gap between judicial procurement price and CONITEC-negotiated price is largest.</p>
<p><strong>Pre-existing evidence:</strong></p>
<ul>
<li>BioMarin delayed CONITEC submission for vosoritida: R$875M judicial spend (2022–2024), only planning submission for 2025. [Futuro da Saúde 2025]</li>
<li>Atalureno (Duchenne): R$765M judicial spend (2022–2024) without CONITEC incorporation. [Futuro da Saúde 2025]</li>
<li>Companies &quot;deliberately avoid CONITEC when evidence is weak, preferring judicialization.&quot; [Tamachiro et al. 2022]</li>
<li>52.7% of industry CONITEC requests were rejected. [Tamachiro et al. 2022]</li>
<li>Non-ANVISA-registered drug spending grew 220x in 5 years: R$2.4M (2010) to R$545M (2015). [Estadão 2016]</li>
<li>Pharma companies delay ANVISA registration or CONITEC incorporation to profit from higher non-negotiated judicial prices. [IPEA 2025, p. 577]</li>
<li>~50 lawsuits by foreign pharma to delay generic versions of ~50 medications. [Intercept 2023]</li>
</ul>
<p><strong>Evidence strength: Strong.</strong> The strategic delay pattern is documented by multiple sources including academic studies, investigative journalism, and government reports. However, the causal link (delay → more judicial spending → higher profits) is inferred rather than directly estimated.</p>
<p><strong>Empirical test:</strong> Not directly testable with the Judge-IV design (this is about pharma firm behavior, not municipal outcomes). But can inform interpretation of H3: if the composition of mandated items skews toward drugs that pharma has strategically kept off CONITEC, the procurement waste channel is operating.</p>
<p><strong>Data:</strong> CONITEC recommendations database + TJSP case data (drug classification)</p>
<p><strong>Priority: Medium.</strong> Important for narrative and policy implications but not a direct Judge-IV test.</p>
<hr />
<h2 id="cross-cutting-observations">Cross-Cutting Observations</h2>
<h3 id="which-polar-view-does-the-evidence-support">Which polar view does the evidence support?</h3>
<table>
<thead>
<tr>
  <th>Dimension</th>
  <th>Optimistic (corrective)</th>
  <th>Pessimistic (distortionary)</th>
  <th>Evidence tilts toward</th>
</tr>
</thead>
<tbody>
<tr>
  <td>Information</td>
  <td>Courts elicit local need (Hayek)</td>
  <td>Courts rubber-stamp (93% grant, &lt;6% cite evidence)</td>
  <td><strong>Pessimistic</strong></td>
</tr>
<tr>
  <td>Selection</td>
  <td>Courts serve the underserved</td>
  <td>Litigation skews to better-resourced (64% private attorneys, ~20% vulnerable)</td>
  <td><strong>Pessimistic</strong></td>
</tr>
<tr>
  <td>Supply side</td>
  <td>Patient-driven need</td>
  <td>Lawyer-pharma supply chain (19 lawyers = 63% of cases)</td>
  <td><strong>Pessimistic</strong></td>
</tr>
<tr>
  <td>Procurement</td>
  <td>Courts force provision of needed drugs</td>
  <td>30–44% price premium, expired stockpiles, no-bid contracts</td>
  <td><strong>Pessimistic</strong></td>
</tr>
<tr>
  <td>Fiscal incidence</td>
  <td>Courts force higher-level compliance</td>
  <td>Municipalities bear misassigned costs (55% mismatch)</td>
  <td><strong>Pessimistic</strong></td>
</tr>
<tr>
  <td>Admin failure</td>
  <td>SUS genuinely fails to deliver (80% shortages, CONITEC delays)</td>
  <td>Courts don't fix admin failure, just bypass it expensively</td>
  <td><strong>Mixed</strong></td>
</tr>
<tr>
  <td>Dynamic</td>
  <td>Mandates correct persistent underfunding</td>
  <td>Mandates accumulate and rigidify budgets (ratchet)</td>
  <td><strong>Pessimistic</strong></td>
</tr>
<tr>
  <td>Behavioral</td>
  <td>Judges respond to genuine urgency</td>
  <td>Identifiable victim + omission bias → over-granting</td>
  <td><strong>Pessimistic</strong></td>
</tr>
</tbody>
</table>
<p>The strongest counter-evidence for the optimistic view is administrative failure — SUS genuinely does not deliver what it promises (80% shortages, 624-day incorporation delays, 1.6M surgical waiting list). This means some judicial mandates are corrective. The empirical challenge is separating the corrective cases from the distortionary ones, which maps to the heterogeneity analysis (H2, H4, H5, H8).</p>
<h3 id="where-theories-generate-distinct-predictions">Where theories generate distinct predictions</h3>
<table>
<thead>
<tr>
  <th>Comparison</th>
  <th>Theory A predicts</th>
  <th>Theory B predicts</th>
  <th>Discriminating test</th>
</tr>
</thead>
<tbody>
<tr>
  <td>Returns by lawyer type</td>
  <td>SID (#10): low returns for high-volume lawyers</td>
  <td>Capture (#5): low returns everywhere</td>
  <td>Split by lawyer volume (H2)</td>
</tr>
<tr>
  <td>Returns by municipal capacity</td>
  <td>Capture (#5): positive where capacity weakest</td>
  <td>Earmarking (#4): negative everywhere</td>
  <td>Heterogeneity by admin capacity (H8)</td>
</tr>
<tr>
  <td>Returns by drug type</td>
  <td>Grossman (#3): low returns for high-cost drugs</td>
  <td>Fiscal fed (#9): low returns for misassigned drugs</td>
  <td>Heterogeneity by drug component (H4)</td>
</tr>
<tr>
  <td>Effect of information reforms</td>
  <td>Behavioral (#12): NAT-Jus improves allocation</td>
  <td>SID (#10): supply side adapts around reforms</td>
  <td>Pre/post NAT-Jus effects (H6)</td>
</tr>
<tr>
  <td>Dynamic pattern</td>
  <td>Ratchet (#11): effects worsen over time</td>
  <td>Corrective (#5): effects stable or improving</td>
  <td>Event-study dynamics (H7)</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="references">References</h2>
<p>Sources are cited inline using short labels. Full citations available in:</p>
<ul>
<li><code>docs/institutions.md</code> (institutional facts and references)</li>
<li><code>docs/theory.md</code> (theoretical frameworks and academic references)</li>
<li><code>references/news/stories.csv</code> (news sources with URLs)</li>
<li><code>docs/data.md</code> (data source documentation)</li>
</ul>

</div>
</main>

<footer>
  Generated by <code>bash build.sh site</code>
</footer>

<script>
document.addEventListener('DOMContentLoaded', () => {
  const body = document.querySelector('.md-body');
  if (!body) return;

  function foldHeadings(container, tag) {
    const level = tag.replace('H', '');
    const headings = Array.from(container.querySelectorAll(':scope > ' + tag.toLowerCase()));
    headings.forEach(h => {
      const details = document.createElement('details');
      details.className = 'level-' + level;
      if (h.id) details.id = h.id;
      const summary = document.createElement('summary');
      summary.innerHTML = h.innerHTML;
      details.appendChild(summary);
      let sibling = h.nextElementSibling;
      const collected = [];
      while (sibling && sibling.tagName !== tag) {
        collected.push(sibling);
        sibling = sibling.nextElementSibling;
      }
      collected.forEach(el => details.appendChild(el));
      h.replaceWith(details);
    });
    return headings.length;
  }

  // Fold h2 sections, then h3 sections within each h2
  const count = foldHeadings(body, 'H2');
  if (count === 0) {
    document.querySelector('.doc-controls').style.display = 'none';
    return;
  }
  body.querySelectorAll('details.level-2').forEach(d => foldHeadings(d, 'H3'));

  // Toggle button
  const btn = document.getElementById('toggle-sections');
  if (!btn) return;
  btn.addEventListener('click', () => {
    const allDetails = body.querySelectorAll('details');
    const expanding = btn.textContent === 'Expand all';
    allDetails.forEach(d => d.open = expanding);
    btn.textContent = expanding ? 'Collapse all' : 'Expand all';
  });

  // Auto-open details when navigating to an anchor
  function openAnchorTarget() {
    if (!location.hash) return;
    const target = document.querySelector(location.hash);
    if (!target) return;
    let el = target;
    while (el) {
      if (el.tagName === 'DETAILS') el.open = true;
      el = el.parentElement;
    }
    target.scrollIntoView();
  }
  openAnchorTarget();
  window.addEventListener('hashchange', openAnchorTarget);
});
</script>

</body>
</html>
